These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

331 related items for PubMed ID: 21087403

  • 1. A multicenter, randomized, double-blind, controlled study of NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia.
    Irving GA, Backonja MM, Dunteman E, Blonsky ER, Vanhove GF, Lu SP, Tobias J, NGX-4010 C117 Study Group.
    Pain Med; 2011 Jan; 12(1):99-109. PubMed ID: 21087403
    [Abstract] [Full Text] [Related]

  • 2. NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomized, double-blind, controlled study with an open-label extension.
    Backonja MM, Malan TP, Vanhove GF, Tobias JK, C102/106 Study Group.
    Pain Med; 2010 Apr; 11(4):600-8. PubMed ID: 20113411
    [Abstract] [Full Text] [Related]

  • 3. NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomised, double-blind study.
    Backonja M, Wallace MS, Blonsky ER, Cutler BJ, Malan P, Rauck R, Tobias J, NGX-4010 C116 Study Group.
    Lancet Neurol; 2008 Dec; 7(12):1106-12. PubMed ID: 18977178
    [Abstract] [Full Text] [Related]

  • 4. A multicenter, randomized, double-blind, controlled dose finding study of NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia.
    Webster LR, Malan TP, Tuchman MM, Mollen MD, Tobias JK, Vanhove GF.
    J Pain; 2010 Oct; 11(10):972-82. PubMed ID: 20655809
    [Abstract] [Full Text] [Related]

  • 5. Long-term safety of NGX-4010, a high-concentration capsaicin patch, in patients with peripheral neuropathic pain.
    Simpson DM, Gazda S, Brown S, Webster LR, Lu SP, Tobias JK, Vanhove GF, NGX-4010 C118 Study Group.
    J Pain Symptom Manage; 2010 Jun; 39(6):1053-64. PubMed ID: 20538187
    [Abstract] [Full Text] [Related]

  • 6. Effect of duration of postherpetic neuralgia on efficacy analyses in a multicenter, randomized, controlled study of NGX-4010, an 8% capsaicin patch evaluated for the treatment of postherpetic neuralgia.
    Webster LR, Tark M, Rauck R, Tobias JK, Vanhove GF.
    BMC Neurol; 2010 Oct 11; 10():92. PubMed ID: 20937130
    [Abstract] [Full Text] [Related]

  • 7. NGX-4010, a capsaicin 8% dermal patch, administered alone or in combination with systemic neuropathic pain medications, reduces pain in patients with postherpetic neuralgia.
    Irving G, Backonja M, Rauck R, Webster LR, Tobias JK, Vanhove GF.
    Clin J Pain; 2012 Feb 11; 28(2):101-7. PubMed ID: 21753727
    [Abstract] [Full Text] [Related]

  • 8. A randomized vehicle-controlled trial of topical capsaicin in the treatment of postherpetic neuralgia.
    Watson CP, Tyler KL, Bickers DR, Millikan LE, Smith S, Coleman E.
    Clin Ther; 1993 Feb 11; 15(3):510-26. PubMed ID: 8364943
    [Abstract] [Full Text] [Related]

  • 9. Qutenza®: a capsaicin 8% patch for the management of postherpetic neuralgia.
    Wallace M, Pappagallo M.
    Expert Rev Neurother; 2011 Jan 11; 11(1):15-27. PubMed ID: 21158551
    [Abstract] [Full Text] [Related]

  • 10. Capsaicin 8% topical patch (Qutenza)--a review of the evidence.
    Jones VM, Moore KA, Peterson DM.
    J Pain Palliat Care Pharmacother; 2011 Jan 11; 25(1):32-41. PubMed ID: 21426216
    [Abstract] [Full Text] [Related]

  • 11. Pharmacokinetic analysis of capsaicin after topical administration of a high-concentration capsaicin patch to patients with peripheral neuropathic pain.
    Babbar S, Marier JF, Mouksassi MS, Beliveau M, Vanhove GF, Chanda S, Bley K.
    Ther Drug Monit; 2009 Aug 11; 31(4):502-10. PubMed ID: 19494795
    [Abstract] [Full Text] [Related]

  • 12. NGX-4010, a capsaicin 8% dermal patch, for the treatment of painful HIV-associated distal sensory polyneuropathy: results of a 52-week open-label study.
    Simpson DM, Brown S, Tobias JK, Vanhove GF, NGX-4010 C107 Study Group.
    Clin J Pain; 2014 Feb 11; 30(2):134-42. PubMed ID: 23446088
    [Abstract] [Full Text] [Related]

  • 13. Qutenza (capsaicin) 8% patch onset and duration of response and effects of multiple treatments in neuropathic pain patients.
    Mou J, Paillard F, Turnbull B, Trudeau J, Stoker M, Katz NP.
    Clin J Pain; 2014 Apr 11; 30(4):286-94. PubMed ID: 23765045
    [Abstract] [Full Text] [Related]

  • 14. Capsaicin patch (Qutenza) for postherpetic neuralgia.
    Med Lett Drugs Ther; 2011 May 30; 53(1365):42-3. PubMed ID: 21617594
    [Abstract] [Full Text] [Related]

  • 15. A novel approach to identify responder subgroups and predictors of response to low- and high-dose capsaicin patches in postherpetic neuralgia.
    Martini CH, Yassen A, Krebs-Brown A, Passier P, Stoker M, Olofsen E, Dahan A.
    Eur J Pain; 2013 Nov 30; 17(10):1491-501. PubMed ID: 23650124
    [Abstract] [Full Text] [Related]

  • 16. An open-label pilot study of high-concentration capsaicin patch in painful HIV neuropathy.
    Simpson DM, Estanislao L, Brown SJ, Sampson J.
    J Pain Symptom Manage; 2008 Mar 30; 35(3):299-306. PubMed ID: 17959343
    [Abstract] [Full Text] [Related]

  • 17. Predictors of Response in Patients With Postherpetic Neuralgia and HIV-Associated Neuropathy Treated With the 8% Capsaicin Patch (Qutenza).
    Katz NP, Mou J, Paillard FC, Turnbull B, Trudeau J, Stoker M.
    Clin J Pain; 2015 Oct 30; 31(10):859-66. PubMed ID: 25503598
    [Abstract] [Full Text] [Related]

  • 18. Clinical inquiries: What measures relieve postherpetic neuralgia?
    Garroway N, Chhabra S, Landis S, Skolnik DC.
    J Fam Pract; 2009 Jul 30; 58(7):384d-f. PubMed ID: 19607770
    [Abstract] [Full Text] [Related]

  • 19. Cost-effectiveness analysis of a new 8% capsaicin patch compared to existing therapies for postherpetic neuralgia.
    Armstrong EP, Malone DC, McCarberg B, Panarites CJ, Pham SV.
    Curr Med Res Opin; 2011 May 30; 27(5):939-50. PubMed ID: 21375358
    [Abstract] [Full Text] [Related]

  • 20. NGX-4010, a high-concentration capsaicin dermal patch for lasting relief of peripheral neuropathic pain.
    Noto C, Pappagallo M, Szallasi A.
    Curr Opin Investig Drugs; 2009 Jul 30; 10(7):702-10. PubMed ID: 19579176
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.